115 related articles for article (PubMed ID: 20954901)
1. CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity.
Christensen H; Hestad AL; Molden E; Mathiesen L
Xenobiotica; 2011 Jan; 41(1):1-5. PubMed ID: 20954901
[TBL] [Abstract][Full Text] [Related]
2. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
3. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450-dependent metabolism of midazolam in hepatic microsomes from chickens, turkeys, pheasant and bobwhite quail.
Cortright KA; Craigmill AL
J Vet Pharmacol Ther; 2006 Dec; 29(6):469-76. PubMed ID: 17083450
[TBL] [Abstract][Full Text] [Related]
5. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Perloff MD; Von Moltke LL; Greenblatt DJ
Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
[TBL] [Abstract][Full Text] [Related]
6. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
7. Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes.
Gan L; von Moltke LL; Trepanier LA; Harmatz JS; Greenblatt DJ; Court MH
Drug Metab Dispos; 2009 Jan; 37(1):90-6. PubMed ID: 18838505
[TBL] [Abstract][Full Text] [Related]
8. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.
Quintieri L; Palatini P; Nassi A; Ruzza P; Floreani M
Biochem Pharmacol; 2008 Mar; 75(6):1426-37. PubMed ID: 18191104
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
11. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of Shenmai injection, a herbal preparation, on the cytochrome P450 3A-mediated 1'-hydroxylation and 4-hydroxylation of midazolam.
Xia C; Sun J; Wang G; Shang L; Zhang X; Zhang R; Wang X; Hao H; Xie L
Chem Biol Interact; 2009 Aug; 180(3):440-8. PubMed ID: 19557931
[TBL] [Abstract][Full Text] [Related]
13. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
14. Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.
Blobaum AL; Bridges TM; Byers FW; Turlington ML; Mattmann ME; Morrison RD; Mackie C; Lavreysen H; Bartolomé JM; Macdonald GJ; Steckler T; Jones CK; Niswender CM; Conn PJ; Lindsley CW; Stauffer SR; Daniels JS
Drug Metab Dispos; 2013 Dec; 41(12):2066-75. PubMed ID: 24003250
[TBL] [Abstract][Full Text] [Related]
15. UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
Venkatapura Chandrashekar D; DuBois B; Mehvar R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122892. PubMed ID: 34388602
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
19. Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources.
Christensen H; Mathiesen L; Postvoll LW; Winther B; Molden E
Drug Metab Pharmacokinet; 2009; 24(3):261-8. PubMed ID: 19571438
[TBL] [Abstract][Full Text] [Related]
20. Decrease in NADPH-cytochrome P450 reductase activity of the human heart, Liver and lungs in the presence of alpha-lipoic acid.
Dudka J
Ann Nutr Metab; 2006; 50(2):121-5. PubMed ID: 16391466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]